标题:A dose-response meta-analysis of coffee consumption and bladder cancer
作者:Zhou,Y.;Tian,C.;Jia,C.
作者机构:[Zhou, Y] Department of Epidemiology and Health Statistics, Shandong University, China;[ Tian, C] Department of Epidemiology and Health Statistics, Sh 更多
通讯作者:Jia, CQ
通讯作者地址:[Jia, CQ]Shandong Univ, Dept Epidemiol & Hlth Stat, Jinan 250012, Shandong, Peoples R China.
来源:Preventive Medicine: An International Journal Devoted to Practice and Theory
出版年:2012
卷:55
期:1
页码:14-22
DOI:10.1016/j.ypmed.2012.04.020
关键词:Bladder cancer;Coffee;Meta-analysis
摘要:Background: A number of studies have examined the association between coffee consumption and risk of bladder cancer, but uncertainty about the dose-response relationship remains. Materials and methods: A comprehensive search was performed to identify all observational studies providing quantitative estimates between bladder cancer risk and coffee consumption. Dose-response relationship was assessed by restricted cubic spline model and bivariate random-effect meta-regression. Results: 23 case-control studies with 7690 cases and 13,507 controls, and 5 cohort studies with 700 cases and 229,099 participants, met the inclusion criteria. Compared with non-drinkers and for case-control studies, the pooled smoking-adjusted RRs(95% CI) of bladder cancer were 1.07(1.02-1.13) for 1 cup/day, 1.15(1.05-1.26) for 2 cups/day, 1.22(1.08-1.38) for 3 cups/day, and 1.29(1.12-1.48) for 4 cups/day. For cohort studies, the pooled smoking-adjusted RRs of bladder cancer were 1.09(95% CI, 0.89-1.34) for 1 cup/day, 1.13(95% CI, 0.82-1.55) for 2 cups/day, 1.09(95% CI, 0.77-1.56) for 3 cups/day, and 1.01(95% CI, 0.69-1.48) for 4 cups/day. Conclusions: Although data from case-control studies suggested that coffee was a risk factor for bladder cancer, there was no conclusive evidence on this association because of inconsistencies between case-control and cohort studies.
收录类别:SCOPUS;SCIE
WOS核心被引频次:11
Scopus被引频次:16
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862493328&doi=10.1016%2fj.ypmed.2012.04.020&partnerID=40&md5=f29ed22adeebe333f9154967c5132980
TOP